Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
What drives stock market index performance includes macro trends, earnings, and valuation shifts. This overview explains the main forces behind movements.
27,569 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
IREN leaps on a landmark NVIDIA AI Cloud contract and a parallel equity option, signaling a strategic pivot from cryp...
Salesforce is set to release Q1 results as investors look for evidence that its AI strategy can rekindle growth. A re...
Pfizer stock hovers around the $26 level as insiders aren’t buying Pfizer stock. Analysts point to a patient, value-f...
Netflix is trading near its 52-week low as ad-supported growth and cash flow gains reshape investor bets. Analysts di...
Ford is aiming high with an AI-driven energy storage push. This article breaks down what that could mean for investor...
Adobe and Duolingo sit at opposite ends of the tech stock spectrum: one is a cash-generating powerhouse, the other a ...
Poet Technologies faces a pivotal year as AI-driven optical interconnects scale. This report analyzes catalysts, risk...
Could Costco surprise investors with another special dividend in 2026? This guide dives into history, cash flow, and ...
Smart investors don’t chase every hype. They look for durable advantages, strong cash flow, and clear paths to growth...
Hims & Hers beat quarterly EPS but trimmed full-year guidance, extending a slide in its stock as regulatory headwinds...
Oracle just posted best quarter in years, powered by cloud and AI demand. This article breaks down what changed, why ...